How to appeal a Cigna multiple myeloma (non-car-t) denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal a Cigna multiple myeloma (non-car-t) denial, file an internal appeal within 180 days of the date on the denial letter through Cigna's member or provider portal, under ACA §2719 + ERISA §503. Cigna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
What Cigna's policy requires for multiple myeloma (non-car-t)
Cited policy: Cigna Revlimid (Lenalidomide) for MM Induction + Maintenance
MM diagnosis. Induction: VRd, DRd, DVRd, KRd, IRd, ERd. Post-ASCT maintenance: 10 mg daily x 21/28 (or continuous) until progression. REMS Lenalidomide / pomalidomide / thalidomide REMS enrollment. VTE prophylaxis (aspirin 81 mg or therapeutic anticoagulation if higher-risk).
How Cigna denies multiple myeloma (non-car-t) — and how to counter it
Where Cigna pushes back: 1) Maintenance not necessary — observe; 2) Limit maintenance to 2 yr; 3) Not preferred in this line.
Counter-arguments that hold up: CALGB 100104 (McCarthy NEJM 2012;366:1770; long-term JCO 2017) + Myeloma XI (Jackson Lancet Oncol 2019;20:57) — Revlimid maintenance post-ASCT improves PFS by ~25 mo + OS benefit. FDA-approved for maintenance Feb 22, 2017. NCCN MM v3.2024 category-1 maintenance until progression (not 2-year cap). Discontinuation at fixed time-point not supported by long-term follow-up.
What Cigna typically denies for multiple myeloma (non-car-t)
Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For multiple myeloma (non-car-t), expect:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Treatments most often denied in this category
These are the multiple myeloma (non-car-t) treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Darzalex IV
- Darzalex Faspro SC
- Sarclisa
- Tecvayli
- Elrexfio
- Talvey
How to submit the appeal to Cigna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
- File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Cigna multiple myeloma (non-car-t) denial?
Cigna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Cigna appeal?
Members can submit through the Cigna member portal at https://my.cigna.com. Providers should use the provider portal at https://cignaforhcp.cigna.com. Faxed and mailed appeals are accepted but take longer.
What denials does Cigna most often issue for multiple myeloma (non-car-t)?
For multiple myeloma (non-car-t), Cigna most often denies on: 1) Maintenance not necessary — observe; 2) Limit maintenance to 2 yr; 3) Not preferred in this line. The strongest counters: CALGB 100104 (McCarthy NEJM 2012;366:1770; long-term JCO 2017) + Myeloma XI (Jackson Lancet Oncol 2019;20:57) — Revlimid maintenance post-ASCT improves PFS by ~25 mo + OS benefit. FDA-approved for maintenance Feb 22, 2017. NCCN MM v3.2024 category-1 maintenance until progression (not 2-year cap). Discontinuation at fixed time-point not supported by long-term follow-up.
What if Cigna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Multiple myeloma (non-CAR-T) appeal
Upload your Cigna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com